These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. Walker KM, Pope J, Scleroderma Clinical Trials Consortium, Canadian Scleroderma Research Group. J Rheumatol; 2011 Jul; 38(7):1326-8. PubMed ID: 21459952 [Abstract] [Full Text] [Related]
3. Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG). Harding S, Khimdas S, Bonner A, Baron M, Pope J, Canadian Scleroderma Research Group. Clin Exp Rheumatol; 2012 Jul; 30(2 Suppl 71):S38-43. PubMed ID: 22691207 [Abstract] [Full Text] [Related]
5. Update of EULAR recommendations for the treatment of systemic sclerosis. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U, EUSTAR Coauthors. Ann Rheum Dis; 2017 Aug; 76(8):1327-1339. PubMed ID: 27941129 [Abstract] [Full Text] [Related]
13. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. Villela R, Yuen SY, Pope JE, Baron M, Canadian Scleroderma Research group. Arthritis Rheum; 2008 May 15; 59(5):706-13. PubMed ID: 18438906 [Abstract] [Full Text] [Related]
14. Determinants of morbidity and mortality of systemic sclerosis in Canada. Al-Dhaher FF, Pope JE, Ouimet JM. Semin Arthritis Rheum; 2010 Feb 15; 39(4):269-77. PubMed ID: 18706680 [Abstract] [Full Text] [Related]
15. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Walker UA, Tyndall A, Czirják L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Matucci-Cerinic M, EUSTAR co-authors. Ann Rheum Dis; 2009 Jun 15; 68(6):856-62. PubMed ID: 18625615 [Abstract] [Full Text] [Related]
16. Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort. Jung M, Bonner A, Hudson M, Baron M, Pope JE, Canadian Scleroderma Research Group (CSRG). Scand J Rheumatol; 2014 Jun 15; 43(3):217-20. PubMed ID: 24650305 [Abstract] [Full Text] [Related]
18. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature. Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y. Clin Dev Immunol; 2005 Sep 15; 12(3):165-73. PubMed ID: 16295521 [Abstract] [Full Text] [Related]